Cargando…

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19

Detalles Bibliográficos
Autores principales:	Fishbane, Steven, Hirsch, Jamie S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the National Kidney Foundation, Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256552/ https://www.ncbi.nlm.nih.gov/pubmed/32479920 http://dx.doi.org/10.1053/j.ajkd.2020.05.002

Ejemplares similares

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection
por: Shah, Hitesh H., et al.
Publicado: (2020)

Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients
por: Anker, Stefan D., et al.
Publicado: (2009)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Lee, Yu-Ting, et al.
Publicado: (2022)

A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders
por: Das, Monojit, et al.
Publicado: (2022)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Selenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Yasukawa, Minoru, et al.
Publicado: (2022)

The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients
por: Sibbel, Scott, et al.
Publicado: (2016)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia
por: Pashos, Chris L., et al.
Publicado: (2011)

Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
por: Suttorp, Marit M, et al.
Publicado: (2013)

Effect of Erythropoiesis-Stimulating Agents on Blood Pressure in Pre-Dialysis Patients
por: Suttorp, Marit M., et al.
Publicado: (2013)

Mechanisms of hemoglobin cycling in anemia patients treated with erythropoiesis-stimulating agents
por: Jörg, David J., et al.
Publicado: (2023)

Comparison of Patient Survival According to Erythropoiesis-Stimulating Agent Type of Treatment in Maintenance Hemodialysis Patients
por: Kang, Seok Hui, et al.
Publicado: (2023)

Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents
por: Yan, X, et al.
Publicado: (2013)

Erythropoiesis stimulating agents and reno-protection: a meta-analysis
por: Elliott, Steve, et al.
Publicado: (2017)

Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
por: Wish, Jay B.
Publicado: (2020)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
por: Melosky, B.L.
Publicado: (2008)

Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent
por: Pirker, Robert, et al.
Publicado: (2012)

Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
por: Kim, Sun Moon, et al.
Publicado: (2016)

Neuroimaging in Former Preterm Children Who Received Erythropoiesis Stimulating Agents
por: Phillips, Authors: John, et al.
Publicado: (2017)

Resistance to Erythropoiesis-Stimulating Agents Is Associated with Arterial Microcalcification in Early Hemodialysis Patients
por: Won, Hye Sung, et al.
Publicado: (2014)

Regulation of platelet count by erythropoiesis-stimulating agents – iron axis in hemodialysis patients
por: Koike, Kiyomi, et al.
Publicado: (2016)

Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma
por: Horváth-Puhó, Erzsébet, et al.
Publicado: (2018)

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes
por: Hattakitpanitchakul, Saroj, et al.
Publicado: (2021)

Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents
por: van der Weerd, Neelke C., et al.
Publicado: (2012)

Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study
por: Darsonval, Astrid, et al.
Publicado: (2017)

Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection
por: Fishbane, Steven, et al.
Publicado: (2022)

Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality
por: Karaboyas, Angelo, et al.
Publicado: (2020)

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
por: Aapro, M, et al.
Publicado: (2012)

Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients
por: Amnuay, Kamalas, et al.
Publicado: (2019)

Ferric Carboxymaltose and Erythropoiesis-Stimulating Agent Treatment Reduces the Rate of Blood Transfusion in Refractory Anemia
por: Gidaro, Antonio, et al.
Publicado: (2022)

Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Combination treatment with an erythropoiesis-stimulating agent and intravenous iron alleviates anaemia in patients with hereditary haemorrhagic telangiectasia
por: Cherif, Honar, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fir465th48n1vaan8jl58dbt7s